Abstract: TH-PO505
12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G
Session Information
- Glomerular Diseases: Clinical, Outcomes, Trials - I
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials
Authors
- Nester, Carla Marie, University of Iowa Molecular Otolaryngology and Renal Research Laboratories, Iowa City, Iowa, United States
- Eisenberger, Ute, Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
- Karras, Alexandre, Hopital Europeen Georges Pompidou, Paris, Île-de-France, France
- Lightstone, Liz, Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom
- Praga, Manuel, Department of Medicine, Complutense University. Hospital Universitario 12 de Octubre, Madrid, Spain
- Remuzzi, Giuseppe, Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy
- Soler, Maria Jose, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain
- Liu, Junhao, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Meier, Matthias, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
- Tawfik, Ronda, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Junge, Guido, Novartis Institutes for BioMedical Research Basel Department of Translational Medicine, Basel, Basel-Stadt, Switzerland
- Biondani, Andrea, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
- Trapani, Angelo J., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Webb, Nicholas, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
- Wong, Edwin Kwan Soon, Newcastle University, Newcastle upon Tyne, United Kingdom
Background
Iptacopan (LNP023) is an oral, first-in-class, selective inhibitor of factor B, a key component of the alternative complement pathway (AP). We have previously reported data from a Ph2 study in native and recurrent C3G (NCT03832114) showing that 12W iptacopan treatment results in a 45% reduction in proteinuria in native C3G. Here we present the effects of 12M iptacopan treatment.
Methods
Adults with native (CoA) or recurrent C3G post kidney transplant (CoB) received iptacopan for at least 12W before entering this Ph2 extension trial (NCT03955445). The primary efficacy objective was to assess the effect of iptacopan on a composite endpoint of 1) stable/improved eGFR [≤10% reduction from baseline], 2) ≥50% reduction from baseline in UPCR, and 3) ≥50% increase from baseline in serum C3 after 12M treatment.
Results
Of 27 patients completing the 12W Ph2 study, 26 (16CoA, 10CoB) entered the extension for treatment with iptacopan 200mg b.i.d. 53% of CoA patients met the composite renal endpoint criteria at 12M; proteinuria was reduced by 57% (p<0.0001; Fig1), eGFR increased by 6.83 mL/min/1.73 m2 (p=0.0174; Fig2) and C3 increased by 253% (p<0.0001). eGFR was stable and C3 levels increased by 96% in CoB. Proteinuria reduction was not assessed in CoB as median baseline proteinuria was normal (18.4g/moL). Iptacopan was generally well-tolerated and most AEs were of mild severity in both cohorts. Biomarkers demonstrated substantial AP inhibition.
Conclusion
Long-term treatment with iptacopan results in further proteinuria reduction and eGFR improvement beyond that previously reported following 12W treatment in native C3G. Stable eGFR was seen in recurrent C3G, with stable increases in serum C3 levels found in both cohorts. The ongoing Ph3 APPEAR-C3G (NCT04817618) study is evaluating the efficacy of iptacopan in native C3G patients.
Funding
- Commercial Support –